Nitastin (Simvastatin)

Simvastatin, the active ingredient in Nitastin, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol and triglyceride levels and is prescribed for adults with hypercholesterolemia, mixed hyperlipidemia, or those at risk of cardiovascular events.

GNH USA supplies Nitastin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support.

Simvastatin acts on cholesterol metabolism and is indicated for several lipid‑related conditions.

Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Hyperlipidemia: lowers triglycerides and modestly raises HDL‑cholesterol. Cardiovascular risk reduction: decreases incidence of myocardial infarction, stroke and related events in patients with established risk factors.

Simvastatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Muscle pain or weakness: mild myalgia without laboratory abnormalities. - Elevated liver enzymes: transient increase in ALT/AST. - Headache: occasional tension‑type headache. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Acute liver injury: marked elevation of transaminases with jaundice. - Severe allergic reaction: rash, angioedema or anaphylaxis. - Myopathy with high CK: significant creatine kinase rise requiring discontinuation.

When prescribing simvastatin, clinicians should observe several safety measures to minimize risk. - Liver function monitoring: obtain baseline ALT/AST and repeat periodically. - Muscle symptom assessment: educate patients to report unexplained myalgia or weakness. - Drug interaction review: avoid concomitant use of strong CYP3A4 inhibitors. - Dose adjustment in renal impairment: consider lower doses in patients with severe renal dysfunction. - Pregnancy and lactation: discontinue therapy as safety is not established. - Store at room temperature: keep in original container, protect from moisture and heat.

Simvastatin interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): markedly raise simvastatin levels and risk of myopathy. - Gemfibrozil: synergistic increase in muscle toxicity. - Protease inhibitors (e.g., ritonavir): potentiate simvastatin exposure.

Moderate Interactions (Monitor Closely): - Amiodarone: may modestly increase muscle adverse events. - Warfarin: can enhance anticoagulant effect, requiring INR monitoring.